An Open-label, Non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children With Myotonic Disorders
Latest Information Update: 09 May 2024
At a glance
- Drugs Mexiletine (Primary)
- Indications Myotonic dystrophy; Nondystrophic myotonia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Lupin
- 03 May 2024 Planned End Date changed from 12 Mar 2024 to 8 Aug 2024.
- 03 May 2024 Planned primary completion date changed from 12 Mar 2024 to 24 Jun 2024.
- 04 Oct 2023 Planned primary completion date changed from 27 Jan 2024 to 12 Mar 2024.